Menu

Relieving IBD with duvakitug.

Nature reviews. Gastroenterology & hepatology · 1 Oct 2026 · Journal Article

Ray

Abstract ↗AI summary

The abstract is read at the publisher; the summary is JClub's.

The AI summary for this paper is being written. Open it in JClub to read the paper with the summary as soon as it lands.

Read the AI summary in JClub →

Efficacy and safety of duvakitug in patients with Crohn's disease (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial.
The lancet. Gastroenterology & hepatology · 1 Sept 2026 · Randomized Controlled Trial
Duvakitug demonstrated a significant endoscopic response in 48% of patients with Crohn's disease, with the 900 mg dose exceeding placebo response rates in a phase 2b trial.
- 7 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42462749
Open in JClub
Efficacy and safety of duvakitug in patients with ulcerative colitis (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial.
The lancet. Gastroenterology & hepatology · 1 Sept 2026 · Randomized Controlled Trial
Duvakitug significantly improved clinical remission rates in patients with moderate to severe ulcerative colitis, with response rates of up to 48% at week 14.
- 7 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42462750
Open in JClub

Journals this month

All journals →

Topics moving, week to 4 Oct 2026

By field

All journals by field →